www.tickerreport.com ·
Artiva Biotherapeutics Nasdaqartv CEO Sells 244315 16 in Stock
Topic context
This topic has been covered 409506 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedInsider sale by CEO of Artiva Biotherapeutics (NASDAQ:ARTV) for tax withholding, not a discretionary sale. Stock declined 7.3% on the news and weak earnings. No direct commercial mechanism affecting product prices, supply chains, or margins. The event is company-specific and does not signal sector-wide changes.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- CEO Fred Aslan sold 27,116 shares at $9.01 for $244,315.16 on May 19, 2026.
- Stock price fell 7.3% to $8.55 on the same day.
- Quarterly loss of $0.95 per share missed analyst expectations.
- CEO retained 1,535,082 shares valued at ~$13.83 million.
- Sale was for tax withholding obligations on equity awards.
No sector-wide commercial impact expected; Artiva's event is company-specific and will fade within weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
timesofindia.indiatimes.com
Fuel Rates Hiked Petrol Price Increased From Rs 94 77 to Rs 97 77 Diesel From Rs 87 67 to Rs 90 67 Check New List of Rates
auto.economictimes.indiatimes.com